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Abstract
Background: The last decade has seen a number of methodological developments in meta-analysis of diagnostic
test studies. However, it is unclear whether such developments have permeated the wider research community
and on which applications they are being deployed. The objective was to assess the uptake and deployment of
the main methodological developments in the meta-analysis of diagnostic tests, and identify the tests and target
disorders most commonly evaluated by meta-analysis.
Methods: Design - systematic review. Data Sources - Medline, EMBASE, CINAHL, Cochrane, PsychInfo, Global health,
HMIC, and AMED were searched for studies published before 31
st December 2008. Selection criteria - studies were
included if they satisfied all of the following: evaluated a diagnostic test; measured test performance; searched two
or more databases; stated search terms and inclusion criteria; used a statistical method to summarise performance.
Data extraction - included the following data items: year; test; reference standard; target disorder; setting; statistical
and quality methods.
Results: 236 studies were included. Over the last 5 years the number of meta-analyses published has increased,
but the uptake of new statistical methods lags behind. Pooling the sensitivity and specificity and using the SROC
remain the preferred methods for analysis in 70% of studies, with the bivariate random effects and HSROC model
being used in only 22% and 5% of studies respectively. In contrast, between 2006 and 2008 the QUADAS tool was
used in 40% of studies. Broadly, radiological imaging was the most frequent category of tests analysed (36%), with
cancer (22%) and infection (21%) being the most common categories of target disorder. Nearly 80% of tests
analysed were those normally used in specialist settings.
Conclusion: Although quality assessment in meta-analyses has improved with the introduction of QUADAS, uptake
of the newer statistical methods is still lagging behind. Furthermore, the focus of secondary research seems to be
in evaluating specialist tests in specialist settings, in contrast to the more routine tests and settings encountered in
the majority of clinical practice.
Background
The application of meta-analysis to diagnostic tests has
lagged behind its application to therapeutic trials [1,2],
emerging only in the last fifteen years. In part, this is
due to therapeutic trials benefiting from certain design
features not afforded diagnostic studies: the randomised
controlled trial design, combined with the use of hard
outcomes such as mortality, greatly facilitates the
validity of the measured effects reported [1]. Also these
measured effects can be adequately summarised by a
single statistic such as an odds ratio [3].
In contrast, test accuracy studies tend to be cross sec-
tional in design [4,5], in order to adequately reflect the
influence that the patient case-mix or ‘spectrum’ may
have on a test’s performance [6,7]. This is measured in
terms of the test’s ability to discriminate those with dis-
ease from those without. Unfortunately, obtaining a sub-
ject’s true disease status is not always free from
ambiguity and relies upon the fidelity of the reference
standard [8]. Even with satisfactory study design and
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is hampered by there not being a single adequate statis-
tic [9] which both describes its accuracy and has clinical
utility in practice.
Hence two statistics, the sensitivity and specificity, are
normally used when summarising a test’s performance,
and via Bayes’ theorem [10] these have the added benefit
of being useful to practitioners. The complication is that
they are not independent: both vary with the threshold
for a positive test result [11]. While this has long been
recognised, and may be graphically depicted by a recei-
v e ro p e r a t o rc h a r a c t e r i s t i c( R O C )c u r v e[ 1 2 , 1 3 ] ,i ti s
only recently that the association has been incorporated
within meta-analysis.
Prior to this, the main method for combining studies
was to pool performance characteristics separately using
the same fixed [14] and random effects [15] models devel-
oped in therapeutics. Early attempts at including the asso-
ciation between the sensitivity and specificity involved
making the assumption that the only source of variation
between studies (heterogeneity) was due to changes in the
test threshold. This is the basis of the summary receiver
operating characteristic (SROC) curve [16,17].
The potential to include other sources of heterogene-
ity in models has existed for some time. Yet, it is only
in the last decade that two other approaches, the bivari-
ate random effects model (BRM) [18,19] and hierarchi-
cal SROC (HSROC) model [20], have emerged that
place between-study variation of the sensitivity and spe-
cificity on a firm statistical basis.
Developments in statistical methodology have been
mirrored by advances in methods for assessing the qual-
ity of studies for systematic reviews. This led to the pub-
lication of the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) tool in 2004 [21]. The
Standards for the Reporting of Diagnostic accuracy stu-
dies (STARD) initiative [5] gave a reporting framework
for investigators that undoubtedly improved the quality
of primary studies. Nonetheless, quality assessment had
lacked a standardised approach with a number of gen-
eral and ad hoc tools being suggested over the last
twenty years [22-26]. As a 14 point questionnaire the
QUADAS tool [21] provides investigators with a means
of assessing the major domains that affect a diagnostic
study’s validity. If applied consistently, this may facilitate
inter-study comparisons.
Thus, over the last decade, we have seen significant
progress in the methodology used in the meta-analysis
of diagnostic tests. Unfortunately, some of this progress
has been at the cost of increased complexity that may
inhibit its implementation. It is of interest to establish
whether such developments have permeated the wider
research community. The objective of this systematic
review was to assess the uptake and deployment of the
main methodological developments in the meta-analysis
of diagnostic tests, and to identify the diagnostic tests
and target disorders most commonly evaluated by meta-
analysis.
Methods
Search Strategy
A search strategy was developed aimed at retrieving arti-
cles in secondary research. The following databases were
searched using an OVID interface: Medline, EMBASE,
C I N A H L ,P s y c h I n f o ,G l o b a lH e a l t h ,C o c h r a n e ,H M I C
and AMED. The initial search strategy was conducted in
October 2008 and again in September 2009 to identify
studies published before the 31
st December 2008. The
search strategies for each of the databases are in Addi-
tional file 1. All searches and the removal of duplicate
citations were carried out by one of the reviewers.
Inclusion Criteria
For the purpose of the review, a meta-analysis was con-
sidered to be a special type of systematic review in
which the accepted methods used to construct a sys-
tematic review were followed and the results were
aggregated by statistical methods. A number of other
terms were also defined to remove ambiguity in the
inclusion criteria and to aid reproducibility; the full
details of these may be found in Additional file 2. They
were developed as an algorithm with the first criterion
being applied to the titles and abstracts of all the cita-
tions. Full text articles were then retrieved on those
which either satisfied the first criterion, or when there
was insufficient information to make a decision.
Studies were included if they satisfied all of the follow-
ing criteria: the citation was an original study of a diag-
nostic or screening test; one of the objectives was to
estimate an accepted performance measure of the test;
two or more of the major electronic databases were
searched; three or more search terms were explicitly sta-
ted in the methods; at least one statistical method was
used to combine the studies and summarise the perfor-
mance of the test.
Data Extraction and appraisal
Data were abstracted on the following: year; test; refer-
ence standard; target disorder; patient setting; statistical
methods and correlation; presence of heterogeneity; and
quality assessment tool. Four statistical methods were
specifically searched for as part of the appraisal: pooling
of performance characteristics using a fixed effects [14]
or random effects [15] model; SROC method as
described by Moses and colleagues [16,17]; bivariate
random effects model (BRM) [18,19]; the HSROC curve
as proposed by Rutter and Gatsonis [20]. Similarly, use
of the QUADAS tool [21] was specifically noted.
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dies were conducted by a single reviewer (BHW). A sec-
ond reviewer (MQ) independently carried out the
s e l e c t i o np r o c e s so na1 0 %r a n d o ms a m p l ed r a w nf r o m
the unduplicated set of citations and also independently
extracted and appraised a 10% random sample of the
included studies. The Kappa statistic was used to esti-
mate the level of agreement [27,28] interpretation was
based on recognised criteria [28,29].
Statistical analysis
In addition to inspection, the frequency distributions of
the different methods used were compared. The baseline
measures for comparison were: the number of studies
applying a particular statistical method per year; and the
proportion of the number included studies published
per year reporting the method of interest. The respec-
tive frequency distributions were compared using the
non-parametric Kolmogorov-Smirnov statistic (D) [30]
and the Wilcoxon signed rank test statistic (V) [31].
T h e s ea r ea p p r o p r i a t ew h e nl i t t l ei sk n o w na b o u tt h e
distributions being evaluated. As the BRM and the
HSROC model have been shown, in most cases to be
statistically equivalent [32,33], their respective distribu-
tions were combined when comparing them with the
other methods. A value of p < 0.05 was considered sig-
nificant. The broad categories of tests, target disorders
and patient settings evaluated in the included studies
were summarised using pie charts.
Results
Citation yield
The searches produced 6259 citations, which after
removal of duplicate citations were reduced to 4336 stu-
dies. Screening of the titles and abstracts using the first
criterion excluded a further 3288 studies (see Additional
file 3 for flowchart). Of the remaining studies, the selec-
tion criteria were applied to the full text manuscripts; in
nine studies the complete manuscripts were not
retrieved. Full text review excluded a further 803 stu-
dies, leaving 236 studies to be included for appraisal
(see Additional file 4). For the selection process the
Kappa score was 0.86 indicating ‘near perfect agreement’
between the two reviewers [29].
Uptake and implementation of methods
From figure 1 it is clear that the number of studies,
which met the inclusion criteria has increased markedly
over the last decade. It also shows the distribution of
statistical methods used.
Part of the impetus behind developing more advanced
methods [18-20] was the recognition of widespread het-
erogeneity in diagnostic studies. Accordingly, this was
reported in 70% of the included studies. Despite their
limitations, overall the most popular methods remain
the SROC curve, which was applied in 158 of the stu-
dies, and independent pooling of the sensitivity and the
specificity, which was used in 151 studies. In 107 stu-
dies, both methods were used and there were no
HSROC
SROC & 
Bivariate 
Bivariate 
Figure 1 The distribution of included studies per statistical method per year. Also shown is the year of publication of the seminal papers
corresponding to the statistical methods (arrows).
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(V = 9, p = 0.11; and D = 0.36, p = 0.33).
A simple approach to modelling heterogeneity is that
deployed in the SROC curve, where the transformed
sensitivity and specificity are assumed to follow a linear
relationship [16,17]: an assumption, which may be tested
by calculating the correlation coefficient [34,35]. Despite
this, the correlation coefficient was reported in only 24
(15%) of the studies, which used an SROC curve model.
In contrast to the two previous methods, the uptake of
the BRM and HSROC model since their introduction
has been limited: twenty-five studies used a BRM and
only nine used an HSROC model. Unsurprisingly, their
combined distribution was significantly different from
that of independent pooling (V = 21, p = 0.03; and D =
1, p = 0.002) and the SROC curve (V = 21, p = 0.03;
and D = 1, p = 0.002). The year of publication of the
seminal papers relating to each of these methods is also
shown. It is of interest that the BRM was probably first
proposed in 1993 [18], the same year the SROC was
proposed [16,17]. This study was referenced by five of
the meta-analyses. However, in the field of diagnostics,
the most quoted reference for the BRM is that of
Reitsma and colleagues in 2005 [19], which was cited in
18 studies.
An interesting question is whether using the new
methods (BRM/HSROC) significantly alters the sum-
mary statistics from those derived using the more tradi-
tional methods (independent pooling/SROC). A number
of studies reported using more than one statistical
method to summarise the data. Yet, only one study
explicitly compared the summary performance statistics
derived from independent pooling with those from an
HSROC curve model [36]. In this study, the summary
statistics were not significantly different [36].
Having been recently introduced, and presenting fewer
technical barriers to its implementation, the uptake of the
QUADAS tool by researchers provides a useful compari-
son with that of the new statistical methods (figure 2).
Although 69 studies cited its use, only 51 used it in either
its entirety or a substantial part of it in assessing quality.
Overall, statistical comparisons showed no significant dif-
ferences between the distributions in figure 2, (V = 15,
p = 0.44; and D = 0.5, p = 0.44). However, the recent
trend (last 3 years) is that the use of QUADAS exceeded
the combined use of the BRM and the HSROC model by
over 10% each year.
An error that is sometimes made when implementing
quality assessment tools is to sum the scores of the indi-
vidual categories. Total scores are based on the implicit
assumption that the different domains on quality are
comparable on a linear scale, which has no validity. Yet,
nearly half (49%) of the studies using the QUADAS tool
reported an overall quality scores.
T h ee v i d e n c et a b l e sf o rt h ei n d i v i d u a ls t u d i e sm a yb e
found in Additional file 5.
2. Characteristics of the included studies
The included studies frequently evaluated more than
one test, on more than one target disorder, and in more
than one setting. There were a total of 685 separate test
evaluations, which were analysed in terms of category of
test (figure 3), category of target disorder (figure 4) and
patient setting (figure 5). Classification was based on a
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Figure 2 Uptake of the new statistical methods (bivariate and HSROC) compared with the uptake of the quality assessment tool
QUADAS.
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Page 4 of 8combination of evidence from the individual studies,
guidance from ICD-10 [37] and clinical experience.
Note that in the following paragraphs, numbers given
represent the number of separate evaluations, not the
number of studies.
Radiological imaging tests were the most common
type of test appraised, with ultrasound (69), magnetic
resonance (64) and computer tomography (53) being the
most frequent technologies evaluated (figure 3).
Although 26% of tests analysed were categorised as clin-
ical, this total is somewhat skewed by six studies, which
accounted for nearly half of the clinical tests (figure 3).
Broadly, cancer (147) and infection (145) were the
most frequent categories of target disorder appearing in
the included studies (figure 4) with tuberculosis (50),
stable coronary artery disease (36) and gallstones and
cholecystitis (33) being the most common conditions.
Although the investigation of cancer varied, a common
theme was the evaluation of imaging technologies to
s t a g et h ed i s e a s ea f t e rt h ep r i m a r yl e s i o nh a da l r e a d y
been identified. Ischaemic heart disease (87) also
appeared repeatedly as a target disorder of interest,
either as an acute manifestation (acute coronary syn-
drome, or myocardial infarction) or as a chronic one
(coronary artery disease, exertional angina).
The typical populations in which the tests would be
a p p l i e di np r a c t i c ea r es h o w ni nf i g u r e5 .T h em o s t
striking feature from the tests evaluated is the propor-
tion that would be used in a secondary (or greater) care
setting. Although there is an even distribution across
the sub-specialties, 87% of the diagnostic tests in the
studies are hospital based (figure 5).
A description of the characteristics for the individual
studies may be found in Additional file 6.
Discussion
Summary of evidence
Over the past decade the number of meta-analyses pub-
lished in diagnostic research has clearly increased.
Although our stricter criteria excluded some of the ear-
lier publications, the recent surge in reporting is both a
reflection of increased interest in the field and greater
attention to quality by investigators.
Notwithstanding the obvious interest and likely
improvement in standards, meta-analysis in diagnostic
research still poses a number of difficulties to research-
ers. The studies appraised in this review seemed to
demonstrate a lack of consensus on how best to aggre-
gate results: in nearly two thirds of studies two or more
statistical methods were used and in some instances up
to four methods were employed.
The SROC curve [16,17] and pooling of the sensitivity
and specificity [14,15] remain the most popular methods
Figure 3 Distribution of broad categories of tests analysed.
Figure 4 Distribution of tests analysed per target disorder
category.
Figure 5 Distribution of tests analysed per patient setting.
Secondary care specialties shown in red.
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Page 5 of 8for summarising diagnostic studies, despite both having
technical shortcomings. To overcome these deficiencies
the bivariate random effects [18,19] and the HSROC
model [20] were independently proposed; but their use
by research groups in the studies appraised was limited.
As part of the normal process a delay between pro-
posal and deployment by the wider research commu-
nity should be expected. If the uptake of the SROC
curve is representative, then figure 1 shows that it
could be at least 10 years before researchers substan-
tially apply the new models. However, this does not
explain the discrepancy between the use of the new
statistical methods and the QUADAS tool [21], which
in the last three years was more widely applied by
investigators (figure 2).
Whereas pooling the sensitivity and the specificity or
constructing an SROC curve may be easily achieved
using, for example, a spreadsheet, the same cannot be
said of either of the newer models. Both of these use
maximum likelihood estimation of the population para-
meters and in the case of the HSROC model, Monte
Carlo simulation may be required, particularly when a
Bayesian approach is taken [20,38]. Thus, specialist sta-
tistical software is needed and with it a technical knowl-
edge [9] which may not be available to a number of
research groups.
To widen access, software packages have recently
become available which incorporate the BRM and
HSROC models. These include: METANDI written in
STATA [39]; METADAS written in SAS [39]; and Diag-
Meta [40] and INLA [41] both written in R. The latter
two, being written in R, have the advantage of being
freely available on the Internet. However, even with
increasing availability of dedicated software, for those
without a technical knowledge they remain ‘black
boxes’. This may, in part, explain a lack of uptake of the
new methods.
Perhaps an equally important issue is the relevance of
the results produced by meta-analysis. The SROC curve
model gives a performance curve with no indication of
the corresponding threshold for individual points on the
curve. The two newer models are able to produce sum-
mary estimates of the sensitivity and specificity. These
take into account all possible variances within and
between the studies analysed, yet do not say how a test
may perform in any particular setting [9]. Recently there
has been an argument in favour of moving towards pre-
diction regions, which define the region where the true
performance of future studies conducted may lie [9,32].
However, this just provides a further iteration to the
research process without necessarily addressing the
issue of transferability of results into practice.
There has undoubtedly been a shift in the thinking on
meta-analysis towards a multivariate approach, as it is
considered more ‘statistically rigorous’ than other meth-
ods [9].
Statistical rigour in itself may not be a sufficient argu-
ment for advocating uptake of the new bivariate meth-
ods; particularly, if the summary estimates generated are
not significantly different from those derived from sim-
pler univariate methods. There were no significant dif-
ferences in the one study identified in this review that
compared the two approaches [36]. However, Harbord
and colleagues have found that estimates of the sensitiv-
ity and specificity may differ by greater than 10% in
some cases [9]. Such differences do not necessarily
translate into changes in clinical decisions: Simel and
Bossuyt found only modest differences in estimates of
the likelihood ratios and importantly, posterior probabil-
ities, when univariate and bivariate methods were com-
pared [42].
It seems this new paradigm is going through an
articulation process where its boundaries and uses are
still being defined [9,43,44]. One potential use for the
new methods is in comparative analyses between two
different tests [3], in order to determine which test is
more accurate overall without knowing their individual
accuracies. But as they currently stand the transferability
of summary estimates from the new methods is far from
clear.
The distribution of tests analysed in the included stu-
dies is also telling, demonstrating incongruence between
research and patient need. The diagnostic process has
been notably analysed in the early work of Crombie,
Hampton et al, and later Sandler [45-47]. These showed
that between 70-90% of the patients are correctly diag-
nosed clinically by the history and examination [45-47].
Yet, in the secondary research analysed here, clinical
tests represented only 26% of the diagnostic tests ana-
lysed. This imbalance is unlikely to change as priority is
given to the evaluation of emerging new technologies
[48,49].
There is similar incongruence between the settings
where most patients are seen in practice and the settings
w h e r et h et e s t sw e r ea n a l y s e d .T h ev a s tm a j o r i t yo f
patients in practice are either seen in a primary care or
an emergency care setting [50,51], but it seems that sec-
ondary research, at least, is being directed towards eval-
uating diagnostic tests which are mainly used in
specialist settings.
Designing a study to evaluate a clinical test particu-
larly in a primary care setting is hampered by the avail-
ability of an adequate reference standard [52]. The
reference standards which involve imaging, histology, or
a specialist diagnosis are more likely to be available in a
secondary care setting than a primary care setting.
Also applying a suitable reference standard to primary
care patients may be constrained by ethical
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considered low risk, but the reference standard carries
potential hazards. This is not the case when the test is
being used to stage an already identified cancer. Here
there is a significant risk of inappropriate treatment and
decreased life expectancy by not performing such a test
for the patient. This, in part, explains the number of
studies evaluating imaging technologies to stage patients
with cancer.
Limitations of study
This study has some limitations. A single reviewer per-
formed both the study selection and the data extraction.
To measure the reproducibility, a second reviewer, blinded
to the results, independently carried out each of these pro-
cesses on two separate 10% random samples. Agreement
between the reviewers was measured using the kappa sta-
tistic and this demonstrated ‘good to excellent agreement’
for both the study selection and data extraction. Nonethe-
less, this method is still more likely to yield errors over the
preferred method of complete, independent replication of
both steps by at least two reviewers.
What may be considered a meta-analysis of diagnostic
test studies is not without ambiguity. The definition used
here was one, which encompassed sound systematic
review principles and used recognised methods to aggre-
gate the results. Inevitably such a definition leads to tight
inclusion criteria and this is reflected by the number of
studies included, which are perhaps fewer than might be
expected from earlier reviews of the field [53].
Conclusions
In summary, there is still limited uptake of the new sta-
tistical methods used in meta-analysis of diagnostic test
studies. Although this should change with increased
availability of statistical software, it remains unclear to
what extent these methods will actually benefit clinical
practice.
More broadly, if the studies reviewed here are repre-
sentative of diagnostic research in general, there appears
to be a disconnect between the focus of investigators on
specialist tests in specialist settings and the type of tests
and settings actually encountered in the majority of clin-
ical practice.
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